Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Secreted Brain-Derived Neurotrophic Factor and Asthma Severity
Wang, Shengyu , Sathish, Venkatachalem , Freeman, Michelle, Prakash, Y. S. , Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S , Sathish, Venkatachalem

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | February 1, 2016 | Volume: 54 | Issue: 2 | Pages: 297-297

10.1165/rcmb.2015-0265le | PMID 26829500 Get It

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer
Group, Australian Ovarian Cancer Study, Study, Australian Cancer, Johnatty, Sharon E. , Lu, Yi , Beesley, Jonathan, Gao, Bo , Kalimutho, Murugan , Henderson, Michelle J. , Russell, Amanda J. , Kar, Siddhartha , Chen, Xiaoqing, Hillman, Kristine M. , Kaufmann, Susanne, Sivakumaran, Haran , O’Reilly, Martin, Wang, Chen , Korbie, Darren , Lambrechts, Diether , Despierre, Evelyn, Nieuwenhuysen, Els Van , Lambrechts, Sandrina, Vergote, Ignace , Lester, Jenny, Oršulić, Sandra , Walsh, Christine M. , Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Matsuo, Keitaro , Hosono, Satoyo , Pisterer, Jacobus, Hillemanns, Peter , Nakanishi, Toru , Yatabe, Yasushi , Goodman, Marc T. , Lurie, Galina, Matsuno, Rayna K., Thompson, Pamela J., Bean, Yukie T., Heitz, Florian , Harter, Philipp , Schwaab, Ira, Høgdall, Estrid , Jensen, Allan , Høgdall, Claus , Lundvall, Lene, Engelholm, Svend Aage, Brown, Bob, Flanagan, James M. , Metcalf, Michelle, Sellers, Thomas A. , Cunningham, Julie M. , Schildkraut, Joellen M. , Iversen, Ed , Weber, Rachel Palmieri , Brennan, Donal J. , Harnett, Paul R. , Haber, Michelle , Goode, Ellen L. , Lee, Jason S. , Khanna, Kum Kum , Meyer, Kerstin B. , Chenevix‐Trench, Georgia , DeFazio, Anna , Edwards, Stacey L. , MacGregor, Stuart , Brown, Robert , Lambrechts, Diether , Cunningham, Julie, Fazio, Anna de , French, Juliet D. , Group, Australian Ovarian Cancer Study, Study, Australian Cancer, Beesley, Jonathan, Chen, Xiaoqing, Karlan, Beth Y. , Pejovic, Tanja B. , Bois, Andreas du , Kjær, Susanne K. , Brown, Bob, Siddiqui, Nadeem , Fridley, Brooke L. , Berchuck, Andrew , Pharoah, Paul D.P. , Norris, Murray D , Lambrechts, Diether , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Haber, Michelle , Wang, Chen , Brown, Robert , Matsuo, Keitaro , Flanagan, James M , Heitz, Florian , Lambrechts, Diether , Ekici, Arif B , Lu, Yi , MacGregor, Stuart , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Harnett, Paul R , Goodman, Marc T

Mayo Clinic

Oncotarget | January 31, 2016 | Volume: 7 | Issue: 6 | Pages: 6353-6368

10.18632/oncotarget.7047 | PMID 26840454 Get It

The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice
Zhang, Zubin , Tong, Jiefei , Tang, Xiaowen , Juan, Jiaxiang , Cao, Biyin, Hurren, Rose, Chen, Guodong , Taylor, Paul , Xu, Xin , Shi, Chang-Xin, Hou, Jian , Wang, Guanghui , Stewart, A. Keith, Schimmer, Aaron D. , Mao, Xinliang , Chen, Guodong, Du, Juan , Wu, Depei , Moran, Michael F.

Mayo Clinic

Blood | January 30, 2016 | Volume: 127 | Issue: 13 | Pages: 1676-1686

10.1182/blood-2015-07-658203 | PMID 26825710 Get It

Key Points HERC4 is the first identified ubiquitin ligase that mediates c-Maf ubiquitination and degradation. HERC4 suppresses MM cell proliferation and delays MM tumor growth.
Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Weekes, Colin D. , Lamberts, Laetitia E., Voortman, Johannes, Diamond, Jennifer R. , Vries, Elisabeth G.E. de , Verheul, Henk M.W. , Kim, George P., Wang, Yulei , Scales, Suzie J. , Samineni, Divya , Brunstein, Flávia, Choi, YounJeong, Maslyar, Daniel, Colón‐Otero, Gerardo , McWilliams, Robert R. , Borad, Mitesh J. , Lieu, Christopher H. , de Vries, Elisabeth G E

Mayo Clinic

Molecular Cancer Therapeutics | January 29, 2016 | Volume: 15 | Issue: 3 | Pages: 439-447

10.1158/1535-7163.mct-15-0693 | PMID 26823490 Get It

Abstract DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2–2.8 mg/kg; q3w) or weekly (0.8–1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventy-one patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n = 54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n = 17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer. Mol Cancer Ther; 15(3); 439–47. ©2016 AACR.
MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus
Bansal, Ajay , Gupta, Vijayalaxmi , Wang, Kenneth T.

Mayo Clinic

Journal of Cellular Biochemistry | January 25, 2016 | Volume: 117 | Issue: 6 | Pages: 1288-1295

10.1002/jcb.25497 | PMID 26808728 Get It

ABSTRACTThe rapid increase and poor survival of esophageal adenocarcinoma (EAC) have led to significant efforts to promote early detection. Given that the premalignant lesion of Barrett's esophagus (BE) is the major known risk factor for EAC, multiple investigators have studied biomarker signatures that can predict malignant progression of BE to EAC. MicroRNAs, a novel class of gene regulators, are small non‐coding RNAs and have been associated with carcinogenesis. MicroRNAs are ideal biomarkers because of their remarkable stability in fixed tissues, a common method for collection of clinical specimens, and in blood either within exosomes or as microRNA‐protein complexes. Multiple studies show potential of microRNAs as tissue and blood biomarkers for diagnosis and prognosis of EAC but the results need confirmation in prospective studies. Although head‐to‐head comparisons are lacking, microRNA panels require less genes than messenger RNA panels for diagnosis of EAC in BE. MicroRNA diagnostic panels will need to be compared for accuracy against global measures of genome instability that were recently shown to be good predictors of progression but require sophisticated analytic techniques. Early studies on blood microRNA panels are promising but have found microRNA markers to be inconsistent among studies. MicroRNA expression in blood is different between various microRNA sub‐compartments such as exosomes and microRNA‐protein complexes and could affect blood microRNA measurements. Further standardization is needed to yield consistent results. We have summarized the current understanding of the tissue and blood microRNA signatures that may predict the development and progression of EAC. J. Cell. Biochem. 117: 1288–1295, 2016. © 2016 Wiley Periodicals, Inc.
Intraneural ganglion cysts: a systematic review and reinterpretation of the world's literature
Desy, Nicholas M. , Wang, Huan , Elshiekh, Mohanad Ahmed Ibrahim, Tanaka, Shota , Choi, Tae Woong, Howe, B. Matthew, Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2016 | Volume: 125 | Issue: 3 | Pages: 615-630

10.3171/2015.9.jns141368 | PMID 26799306 Get It

OBJECTIVE The etiology of intraneural ganglion cysts has been controversial. In recent years, substantial evidence has been presented to support the articular (synovial) theory for their pathogenesis. The authors sought to 1) perform a systematic review of the world's literature on intraneural cysts, and 2) reinterpret available published MR images in articles by other authors to identify unrecognized joint connections. METHODS In Part 1, all cases were analyzed for demographic data, duration of symptoms, the presence of a history of trauma, whether electromyography or nerve conduction studies were performed, the type of imaging, surgical treatment, presence of a joint connection, intraneural cyst recurrence, and postoperative imaging. Two univariate analyses were completed: 1) to compare the proportion of intraneural ganglion cyst publications per decade and 2) to assess the number of recurrences from 1914 to 2003 compared with the years 2004–2015. Three multivariate regression models were used to identify risk factors for intraneural cyst recurrence. In Part 2, the authors analyzed all available published MR images and obtained MR images from selected cases in which joint connections were not identified by the original authors, specifically looking for unrecognized joint connections. Two univariate analyses were done: 1) to determine a possible association between the identification of a joint connection and obtaining an MRI and 2) to assess the number of joint connections reported from 1914 to 2003 compared with 2004 to 2015. RESULTS In Part 1, 417 articles (645 patients) were selected for analysis. Joint connections were identified in 313 intraneural cysts (48%). Both intraneural ganglion cyst cases and cyst recurrences were more frequently reported since 2004 (statistically significant difference for both). There was a statistically significant association between cyst recurrence and percutaneous aspiration as well as failure to disconnect the articular branch or address the joint. In Part 2, the authors identified 43 examples of joint connections that initially went unrecognized: 27 based on their retrospective MR image reinterpretation of published cases and 16 of 16 cases from their sampling of original MR images from published cases. Overall, joint connections were more commonly found in patients who received an MRI examination and were more frequently reported during the years 2004 to 2015 (statistically significant difference for both). CONCLUSIONS This comprehensive review of the world's literature and the MR images further supports the articular (synovial) theory and provides baseline data for future investigators.
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth
Hu, Brian , Fairey, Adrian, Madhav, Anisha, Yang, Dongyun , Li, Meng , Groshen, Susan , Stephens, Craig, Kim, Philip H., Virk, Navneet, Martin, Sue Ellen , Erho, Nicholas , Jenkins, Robert B., Den, Robert B. , Xu, Tong , Xu, Yucheng, Gill, Inderbir S. , Goldkorn, Amir , Wang, Lina , Davicioni, Elai , Quinn, David I , Den, Robert B , Gill, Inderbir S

Mayo Clinic

The Prostate | January 16, 2016 | Volume: 76 | Issue: 6 | Pages: 597-608

10.1002/pros.23151 | PMID 26771938 Get It

Stem Cell Therapies for Treatment of Liver Disease
Nicolas, Clara T., Wang, Yujia , Luebke-Wheeler, Jennifer L., Nyberg, Scott L. , Nicolas, Clara, Luebke-Wheeler, Jennifer

Mayo Clinic

Biomedicines | January 6, 2016 | Volume: 4 | Issue: 1 | Pages: 2

10.3390/biomedicines4010002 | PMID 28536370 Get It

Cell therapy is an emerging form of treatment for several liver diseases, but is limited by the availability of donor livers. Stem cells hold promise as an alternative to the use of primary hepatocytes. We performed an exhaustive review of the literature, with a focus on the latest studies involving the use of stem cells for the treatment of liver disease. Stem cells can be harvested from a number of sources, or can be generated from somatic cells to create induced pluripotent stem cells (iPSCs). Different cell lines have been used experimentally to support liver function and treat inherited metabolic disorders, acute liver failure, cirrhosis, liver cancer, and small-for-size liver transplantations. Cell-based therapeutics may involve gene therapy, cell transplantation, bioartificial liver devices, or bioengineered organs. Research in this field is still very active. Stem cell therapy may, in the future, be used as a bridge to either liver transplantation or endogenous liver regeneration, but efficient differentiation and production protocols must be developed and safety must be demonstrated before it can be applied to clinical practice.
Variability of Brain Death Policies in the United States
Greer, David M. , Wang, Hilary H., Robinson, Jennifer D. , Varelas, Panayiotis N. , Henderson, Galen V., Wijdicks, Eelco F. M. , Greer, David Matthew

Mayo Clinic

JAMA Neurology | December 31, 2015 | Volume: 73 | Issue: 2 | Pages: 213

10.1001/jamaneurol.2015.3943 | PMID 26719912 Get It

HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy
Liu, Tongzheng , Fang, Yuan , Zhang, Haoxing , Deng, Min , Gao, Bowen , Niu, Nifang, Yu, Jia , Lee, SeungBaek, Kim, Jung-Jin, Qin, Bo , Evans, Debra L., Wang, Liewei , Lou, Wenhui, Xie, Fang , Lee, Seung Baek , Kim, JungJin, Evans, Debra, Lee, SeungBaek , Xie, Fang , Lou, Zhenkun , Lee, Seung Baek

Mayo Clinic

Cancer Research | December 16, 2015 | Volume: 76 | Issue: 3 | Pages: 572-581

10.1158/0008-5472.can-15-0671 | PMID 26676747 Get It

Abstract Elucidating mechanisms of chemoresistance is critical to improve cancer therapy, especially for the treatment of pancreatic ductal adenocarcinoma (PDAC). Genome-wide association studies have suggested the less studied gene HEAT repeat-containing protein 1 (HEATR1) as a possible determinant of cellular sensitivity to different chemotherapeutic drugs. In this study, we assessed this hypothesized link in PDAC, where HEATR1 expression is downregulated significantly. HEATR1 silencing in PDAC cells increased resistance to gemcitabine and other chemotherapeutics, where this effect was associated with increased AKT kinase phosphorylation at the Thr308 regulatory site. Mechanistically, HEATR1 enhanced cell responsiveness to gemcitabine by acting as a scaffold to facilitate interactions between AKT and the protein phosphatase PP2A, thereby promoting Thr308 dephosphorylation. Consistent with these findings, treatment with the AKT inhibitor triciribine sensitized HEATR1-depleted PDAC cells to gemcitabine, suggesting that this therapeutic combination may overcome gemcitabine resistance in patients with low HEATR1 expression. Clinically, we found that HEATR1 downregulation in PDAC patients was associated with increased AKT phosphorylation, poor response to tumor resection plus gemcitabine standard-of-care treatment, and shorter overall survival. Collectively, our findings establish HEATR1 as a novel regulator of AKT and a candidate predictive and prognostic indicator of drug responsiveness and outcome in PDAC patients. Cancer Res; 76(3); 572–81. ©2015 AACR.